drugset
drugset / Trial / NCT03403725

MEN1309 I.v. Infusion in Pts With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory NHL Ph I Study

NCT03403725 ↗

Phase 1 Terminated 28 enrolled Menarini Group
NaSequentialOpen-labelTreatment

Summary

The purpose of this clinical trial is to identify the highest dose of MEN1309 drug with acceptable safety profile and that can be used in patients affected by CD205-positive solid tumors and Non-Hodgkin Lymphoma

Timeline

Start
2017-08-28
Primary completion
2019-10-22
Completion
2020-01-08

Outcome

Outcome not reported

Stopped: “Terminated after achievement of MTD, without progressing to cohort expansion for Company decision.”

Drugs

EvaluationDrugModalityDoseRoute
Subject OBEROTATUG RAVTANSINE Other / unclassified 0.05 mg/kg Intravenous
Subject OBEROTATUG RAVTANSINE Other / unclassified 0.1 mg/kg Intravenous
Subject OBEROTATUG RAVTANSINE Other / unclassified 0.2 mg/kg Intravenous
Subject OBEROTATUG RAVTANSINE Other / unclassified 0.4 mg/kg Intravenous
Subject OBEROTATUG RAVTANSINE Other / unclassified 0.8 mg/kg Intravenous
Subject OBEROTATUG RAVTANSINE Other / unclassified 1.6 mg/kg Intravenous
Subject OBEROTATUG RAVTANSINE Other / unclassified 2 mg/kg Intravenous
Subject OBEROTATUG RAVTANSINE Other / unclassified 2.4 mg/kg Intravenous
Subject OBEROTATUG RAVTANSINE Other / unclassified 3.36 mg/kg Intravenous

Indications

metastatic neoplasm non-Hodgkin lymphoma